These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 22439666

  • 1. A phase II study for metabolic in vivo response monitoring with sequential 18FDG-PET-CT during treatment with the EGFR-monoclonal-antibody cetuximab in metastatic colorectal cancer: the Heidelberg REMOTUX trial.
    Berger AK, von Gall C, Abel U, Delorme S, Kloor M, Ose J, Weber TF, Stange A, Haag GM, Haberkorn U, Lordick F, Jäger D.
    BMC Cancer; 2012 Mar 22; 12():108. PubMed ID: 22439666
    [Abstract] [Full Text] [Related]

  • 2. The predictive value of 18F-FDG-PET early evaluation in patients with metastatic gastric adenocarcinoma treated with chemotherapy plus cetuximab.
    Di Fabio F, Pinto C, Rojas Llimpe FL, Fanti S, Castellucci P, Longobardi C, Mutri V, Funaioli C, Sperandi F, Giaquinta S, Martoni AA.
    Gastric Cancer; 2007 Mar 22; 10(4):221-7. PubMed ID: 18095077
    [Abstract] [Full Text] [Related]

  • 3. Early metabolic response in sequential FDG-PET/CT under cetuximab is a predictive marker for clinical response in first-line metastatic colorectal cancer patients: results of the phase II REMOTUX trial.
    Berger AK, Lücke S, Abel U, Haag GM, Grüllich C, Stange A, Dietrich M, Apostolidis L, Freitag A, Trierweiler C, von Gall C, Ose J, Giesel F, Weber TF, Lordick F, Haberkorn U, Jäger D.
    Br J Cancer; 2018 Jul 22; 119(2):170-175. PubMed ID: 29961759
    [Abstract] [Full Text] [Related]

  • 4. Early prediction by 18F-FDG PET/CT for progression-free survival and overall survival in patients with metastatic colorectal cancer receiving third-line cetuximab-based therapy.
    Liu FY, Yen TC, Wang JY, Yang TS.
    Clin Nucl Med; 2015 Mar 22; 40(3):200-5. PubMed ID: 25608159
    [Abstract] [Full Text] [Related]

  • 5. Comparison of EORTC criteria and PERCIST for PET/CT response evaluation of patients with metastatic colorectal cancer treated with irinotecan and cetuximab.
    Skougaard K, Nielsen D, Jensen BV, Hendel HW.
    J Nucl Med; 2013 Jul 22; 54(7):1026-31. PubMed ID: 23572497
    [Abstract] [Full Text] [Related]

  • 6. Early 18F-FDG-PET/CT as a predictive marker for treatment response and survival in patients with metastatic colorectal cancer treated with irinotecan and cetuximab.
    Skougaard K, Nielsen D, Jensen BV, Pfeiffer P, Hendel HW.
    Acta Oncol; 2016 Jul 22; 55(9-10):1175-1182. PubMed ID: 27548393
    [Abstract] [Full Text] [Related]

  • 7. Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximab.
    Wadlow RC, Hezel AF, Abrams TA, Blaszkowsky LS, Fuchs CS, Kulke MH, Kwak EL, Meyerhardt JA, Ryan DP, Szymonifka J, Wolpin BM, Zhu AX, Clark JW.
    Oncologist; 2012 Jul 22; 17(1):14. PubMed ID: 22210091
    [Abstract] [Full Text] [Related]

  • 8. Predicting cetuximab accumulation in KRAS wild-type and KRAS mutant colorectal cancer using 64Cu-labeled cetuximab positron emission tomography.
    Achmad A, Hanaoka H, Yoshioka H, Yamamoto S, Tominaga H, Araki T, Ohshima Y, Oriuchi N, Endo K.
    Cancer Sci; 2012 Mar 22; 103(3):600-5. PubMed ID: 22126621
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. 3'-Deoxy-3'-18F-Fluorothymidine and 18F-Fluorodeoxyglucose positron emission tomography for the early prediction of response to Regorafenib in patients with metastatic colorectal cancer refractory to all standard therapies.
    Kim JE, Chae SY, Kim JH, Kim HJ, Kim TW, Kim KP, Kim SY, Lee JL, Oh SJ, Kim JS, Ryu JS, Moon DH, Hong YS.
    Eur J Nucl Med Mol Imaging; 2019 Jul 22; 46(8):1713-1722. PubMed ID: 31041456
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.
    Jean GW, Shah SR.
    Pharmacotherapy; 2008 Jun 22; 28(6):742-54. PubMed ID: 18503402
    [Abstract] [Full Text] [Related]

  • 14. Molecular imaging of therapeutic response to epidermal growth factor receptor blockade in colorectal cancer.
    Manning HC, Merchant NB, Foutch AC, Virostko JM, Wyatt SK, Shah C, McKinley ET, Xie J, Mutic NJ, Washington MK, LaFleur B, Tantawy MN, Peterson TE, Ansari MS, Baldwin RM, Rothenberg ML, Bornhop DJ, Gore JC, Coffey RJ.
    Clin Cancer Res; 2008 Nov 15; 14(22):7413-22. PubMed ID: 19010858
    [Abstract] [Full Text] [Related]

  • 15. Early PET/CT scan is more effective than RECIST in predicting outcome of patients with liver metastases from colorectal cancer treated with preoperative chemotherapy plus bevacizumab.
    Lastoria S, Piccirillo MC, Caracò C, Nasti G, Aloj L, Arrichiello C, de Lutio di Castelguidone E, Tatangelo F, Ottaiano A, Iaffaioli RV, Izzo F, Romano G, Giordano P, Signoriello S, Gallo C, Perrone F.
    J Nucl Med; 2013 Dec 15; 54(12):2062-9. PubMed ID: 24136935
    [Abstract] [Full Text] [Related]

  • 16. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
    Yen LC, Uen YH, Wu DC, Lu CY, Yu FJ, Wu IC, Lin SR, Wang JY.
    Ann Surg; 2010 Feb 15; 251(2):254-60. PubMed ID: 20010090
    [Abstract] [Full Text] [Related]

  • 17. 111In-cetuximab-F(ab')2 SPECT and 18F-FDG PET for prediction and response monitoring of combined-modality treatment of human head and neck carcinomas in a mouse model.
    van Dijk LK, Boerman OC, Franssen GM, Kaanders JH, Bussink J.
    J Nucl Med; 2015 Feb 15; 56(2):287-92. PubMed ID: 25552666
    [Abstract] [Full Text] [Related]

  • 18. Putative contribution of CD56 positive cells in cetuximab treatment efficacy in first-line metastatic colorectal cancer patients.
    Maréchal R, De Schutter J, Nagy N, Demetter P, Lemmers A, Devière J, Salmon I, Tejpar S, Van Laethem JL.
    BMC Cancer; 2010 Jun 30; 10():340. PubMed ID: 20591136
    [Abstract] [Full Text] [Related]

  • 19. Early FDG/PET scanning as a pharmacodynamic marker of anti-EGFR antibody activity in colorectal cancer.
    Krystal GW, Alesi E, Tatum JL.
    Mol Cancer Ther; 2012 Jul 30; 11(7):1385-8. PubMed ID: 22562987
    [Abstract] [Full Text] [Related]

  • 20. First-line single-agent cetuximab in patients with advanced colorectal cancer.
    Pessino A, Artale S, Sciallero S, Guglielmi A, Fornarini G, Andreotti IC, Mammoliti S, Comandini D, Caprioni F, Bennicelli E, Andretta V, Siena S, Sobrero A.
    Ann Oncol; 2008 Apr 30; 19(4):711-6. PubMed ID: 18073221
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.